Close
Close

Anti-Peptide ASQ T cell receptor ((Tg4)-3), pCDTCR1 (TCR-YC0888)

 Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The TCR binds the acetylated N-terminal peptide Ac1–9[4Y] (AcASQYRPSQR) in the context of H-2Aᵘ.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • Peptide ASQ
  • Epitope
  • ASQYRPSQR + ACET(A1)
  • Format
  • Non-Modified TCR
  • Allele
  • H-2Aᵘ
  • Vector Name
  • pCDTCR1
  • Vector Length
  • ~ 8 kb
  • Vector Type
  • Lentiviral vector
  • TCR Clone
  • Tg4
  • Host Species
  • Mouse

Target

  • Introduction
  • Administration of peptides i.n. induces peripheral tolerance in Tg4 myelin basic protein-specific TCR-Tg mice. This is characterized by the generation of anergic, IL-10-secreting CD4+ T cells with regulatory function (IL-10 Treg). Myelin basic protein Ac1–9 peptide analogs, displaying a hierarchy of affinities for H-2 Au (Ac1–9[4K]<<[4A]<[4Y]), were used to investigate the mechanisms of tolerance induction, focusing on IL-10 Treg generation. Repeated i.n. administration of the highest affinity peptide, Ac1–9[4Y], provided complete protection against EAE, while i.n. Ac1–9[4A] and Ac1–9[4K] treatment resulted in only partial protection. Ac1–9[4Y] was also the most potent stimulus for IL-10 Treg generation. Although i.n. treatment with Ac1–9[4A] gave rise to IL-10-secreting CD4+ T cells, the population as a whole was also capable of secreting IFN-γ after an in vitro recall response to Ac1–9[4A] or [4Y]. In addition to IL-10 production, other facets of tolerance, namely, anergy and suppression (both in vitro and in vivo), were affinity dependent, with i.n. Ac1–9[4Y]-, [4A]- or [4K]-treated CD4+ T cells being the most, intermediate and least anergic/suppressive, respectively. These findings demonstrate that the generation of IL-10 Treg in vivo is driven by high signal strength.

Customer Reviews and Q&As

There are currently no customer reviews or questions for Mouse anti-Peptide ASQ T cell receptor ((Tg4)-3), pCDTCR1 (TCR-YC0888). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

TCR Vector Products

Others

Autoimmune Diseases

Hepatoblastoma

Acute myeloid leukemia (AML)

Melanoma

Breast cancer

Viral Infection

Pancreatic cancer

Prostate cancer

Online Inquiry
Products
Global Services
Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.
Copyright © 2024 Creative Biolabs. All Rights Reserved
Cart
    Go to checkout